» Articles » PMID: 38380413

Paediatric Haemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcome of 20 Patients at a Single Institution

Overview
Specialty Pediatrics
Date 2024 Feb 21
PMID 38380413
Authors
Affiliations
Soon will be listed here.
Abstract

Paediatric haemophagocytic lymphohistiocytosis (pHLH) is a potentially life-threatening condition with significant diagnostic and therapeutic difficulties. The purpose of this study was to describe the clinical presentation, the diagnostic challenges, and the outcomes of haemophagocytic lymphohistiocytosis (HLH) in children assessed at Mukalla Hospital, Yemen. Data from 20 medical records of HLH patients admitted between January 2010 and May 2022 were retrospectively analysed. The median age at presentation was 3.5 ± 5.1 years. Male: female ratio was 1:1. The median time for referral to the hospital was 30 ± 64 days. The most common clinical manifestations were fever and pallor in 95% of cases, and splenomegaly (85%). Hepatomegaly, chest, renal and neurological manifestations were detected in 80%, 45%, 15% and 20% of cases, respectively. Bone marrow haemophagocytosis was detected in 60% of cases. Sixteen patients fulfilled the HLH diagnostic criteria, and 11 patients (55%) received the HLH 2004 protocol. Out of the 20 patients, three (15%) patients are alive. Fourteen patients died, with overall mortality of 82.35%. All mortalities were due to HLH disease with multi-organ failure. Relapse was noticed in five patients either during treatment or after full recovery. pHLH is a challenging emergency with a high mortality rate. High clinical suspicion is essential for early detection and intervention to improve the prognosis.

References
1.
Ishii E, Ohga S, Tanimura M, Imashuku S, Sako M, Mizutani S . Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH Study Group. Med Pediatr Oncol. 1998; 30(5):276-83. DOI: 10.1002/(sici)1096-911x(199805)30:5<276::aid-mpo3>3.0.co;2-c. View

2.
Luo Z, Chen Y, Xu X, Zhao N, Tang Y . Prognostic factors of early death in children with hemophagocytic lymphohistiocytosis. Cytokine. 2017; 97:80-85. DOI: 10.1016/j.cyto.2017.03.013. View

3.
Ellis E, Sharp T, Perez-Padilla J, Gonzalez L, Poole-Smith B, Lebo E . Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic Lymphohistiocytosis in Puerto Rico, 2008 - 2013. PLoS Negl Trop Dis. 2016; 10(8):e0004939. PMC: 4996422. DOI: 10.1371/journal.pntd.0004939. View

4.
Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, Neven B, Picard C, Blanche S . Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007; 120(3):e622-8. DOI: 10.1542/peds.2006-3164. View

5.
Weitzman S . Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program. 2011; 2011:178-83. DOI: 10.1182/asheducation-2011.1.178. View